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Abstract
Background: Group B Streptococcus (GBS) is a leading cause of neonatal sepsis where myocardial dysfunction is an
important contributor to poor outcome. Here we study the effects of the GBS pore-forming b-hemolysin/cytolysin (Bh/c)
exotoxin on cardiomyocyte viability, contractility, and calcium transients.
Methodology/Principal Findings: HL-1 cardiomyocytes exposed to intact wild-type (WT) or isogenic Dbh/c mutant GBS, or
to cell-free extracts from either strain, were assessed for viability by trypan blue exclusion and for apoptosis by TUNEL
staining. Functionality of exposed cardiomyocytes was analyzed by visual quantitation of the rate and extent of contractility.
Mitochondrial membrane polarization was measured in TMRE-loaded cells exposed to GBS bh/c. Effects of GBS bh/c on
calcium transients were studied in fura-2AM-loaded primary rat ventricular cardiomyocytes. Exposure of HL-1
cardiomyocytes to either WT GBS or bh/c extracts significantly reduced both rate and extent of contractility and later
induced necrotic and apoptotic cell death. No effects on cardiomyocyte viability or function were observed after treatment
with Dbh/c mutant bacteria or extracts. The bh/c toxin was associated with complete and rapid loss of detectable calcium
transients in primary neonatal rat ventricular cardiomyocytes and induced a loss of mitochondrial membrane polarization.
These effects on viability and function were abrogated by the bh/c inhibitor, dipalmitoyl phosphatidylcholine (DPPC).
Conclusions/Significance: Our data show a rapid loss of cardiomyocyte viability and function induced by GBS bh/c, and
these deleterious effects are inhibited by DPPC, a normal constituent of human pulmonary surfactant.. These findings have
clinical implications for the cardiac dysfunction observed in neonatal GBS infections.
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Introduction
The Gram-positive pathogen Group B Streptococcus (GBS,
Streptococcus agalactiae) is a major cause of pneumonia, sepsis and
meningitis in human newborns [1,2]. Despite recent advances in
universal screening and intrapartum antibiotic prophylaxis, GBS
remains an important cause of neonatal morbidity and mortality
[3–5]. In the more common early-onset form of GBS infection, the
pathogen gains access to the fetus by ascending infection of the
chorioamnion, or alternatively, following aspiration of contami-
nated vaginal fluids during passage through the birth canal [6,7].
Severe early onset GBS disease is characterized by systemic
hypotension, decreased cardiac output, and arterial hypoxemia,
ultimately leading to multiorgan failure [8,9]. These prominent
cardiovascular manifestations are recapitulated experimentally in
rabbits, pigs or sheep challenged with GBS by intravenous infusion
[10–13].
The molecular effectors of GBS-induced cardiac dysfunction
have not been determined. GBS cell wall preparations and culture
supernatants can activate macrophage/monocytes through multi-
ple Toll-like receptors, leading to the release of abundant cytokines
and other proinflammatory mediators that contribute to cell and
organ dysfunction during sepsis [6,14–16]. We hypothesized that
specific GBS microbial products could also have a direct adverse
effect on cardiomyocyte function. Such a phenomenon has
recently been postulated for sepsis secondary to Staphylococcus
aureus and Escherichia coli, since exogenous administration of pore-
forming bacterial exotoxins produced by each species causes
myocardial depression and loss of myocardial contractility in
isolated perfused rat hearts [17–19].
GBS produces a pore-forming exotoxin known as the b-
hemolysin/cytolysin (bh/c) that is responsible for the characterstic
zone of clearing (‘‘b-hemolysis’’) surrounding colonies grown on
blood agar media. Although to date this toxin has not been
purified to homogeneity, the discovery of the cyl operon encoding
the GBS bh/c activity has allowed generation of isogenic bh/c-
deficient mutant strains for analysis of toxin function using in vitro
and in vivo models of disease pathogenesis [20,21]. Within this
operon, the cylE gene represents a candidate structural gene for the
bh/c toxin since heterologous expression of cylE confers hemolysis
to E. coli [21]; however, evidence exists that other GBS cyl genes
contribute to maximal hemolysin production by the pathogen
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pneumocytes [23], brain endothelial cells [24], and macrophages
[25], and to promote GBS-induced mortality in murine or rabbit
models of pneumonia [26], arthritis [27], sepsis [28] and
meningitis [29]; the effects of this potent bacterial toxin on
cardiac function, however, have not been examined.
In the current study, we observe that GBS has the capacity to
impair the function and viability of cultured cardiomyocytes.
Using wild-type (WT) and isogenic b-h/c-deficient (cylE knockout)
mutant GBS, together with cell free extracts from these bacteria,
we determine the b-h/c toxin to play a principle role in this
cardiotoxicity. Inhibition of b-h/c activity abrogates these
changes, suggesting toxin neutralization could represent a
pharmacological target to reduce cardiac complications in GBS
neonatal sepsis.
Results
GBS bh/c impairs cardiomyocyte contractility
HL-1 cardiomyocytes become synchronously contractile in
culture, and this contractility can be easily quantitated by
determining the rate (in beats per minute) and extent (number
of contractile cells per high power field) of contractile activity. To
determine the effect of GBS and its bh/c toxin on cardiomyocyte
function, contractile HL-1 cardiomyocytes were incubated with
either WT GBS or Dbh/c GBS and contractility rate assessed.
Exposure of HL-1 cells to WT GBS at an MOI=1.0 produced a
pronounced decrease in the rate of contractile activity within 1 h
compared to cells treated with an equivalent number of Dbh/c
GBS (Fig. 1A). WT GBS exposed cardiomyocytes that remained
contractile after 1 h exhibited marked asynchronous contractile
activity. Similar effects of WT but not Dbh/c mutant GBS on
cardiomyocyte contractility were also noted at an MOI=10 (data
not shown). When cell-free extracts of GBS were prepared and
added to the cardiomyocytes at 1:100 dilution, only the extracts
from WT and not Dbh/c mutant bacteria had a significant effect
on rate and extent (number of contractile cells per high power
field) of HL-1 contractility at 1 h (Fig. 1A and B). An approximate
60% reduction in cardiomyocyte function was observed at a WT
extract dilution as high as 1:10,000 and as early as 30 min after
exposure (data not shown). No change in contractile activity was
noted for cells exposed to the extract prepared from Dbh/c GBS
even following 4 h exposure (data not shown). These results
suggest that GBS bh/c exerts a direct and rapid effect on
cardiomyocyte function.
GBS bh/c impairs cardiomyocyte viability
To determine if GBS bh/c was inducing cardiomyocyte cell
death, both trypan blue staining and TUNEL staining for
apoptosis were performed on cells exposed to cell free GBS
extracts. Trypan blue staining of HL-1 cells after 1 h of exposure
to extract from WT GBS showed high percentages of dead cells
(Fig. 2A), while such changes were absent in cells treated with
extract of the Dbh/c mutant. DPPC is the major component of
pulmonary surfactant, and its relative absence in the lungs of
premature neonates is believed to contribute to a worse prognosis
for GBS-infected premature infants [30,31]. Addition of DPPC
(2 mg/ml), a known inhibitor of bh/c toxicity to erythrocytes and
epithelial cells [23,32], blocked the cell injury induced by WT
GBS extract (Fig. 2A). Because GBS bh/c has been shown to
induce apoptosis in mammalian cells [25], we investigated whether
evidence of apoptosis could be detected at early timepoints in
hemolysin-exposed cardiomyocytes. After 1 h, a significantly
greater percentage of HL-1 cardiomyocytes exposed to WT
GBS extract were positive for TUNEL stain compared to those
exposed to Dbh/c mutant extract; and the degree of TUNEL
staining was significantly reduced in the presence of DPPC
(Fig 2B). Pretreatment of HL-1 cells with either EGTA (1 mM) to
chelate extracellular calcium or with the cell-permeable calcium
chelator, BAPTA-AM (1 nM), each sufficient to inhibit contractile
activity, had no effect on cell death analyzed by either trypan blue
or TUNEL staining (data not shown), suggesting that the
induction of cell death did not depend on significant levels of
intracellular calcium. Collectively, these data suggest that bh/c
induces a rapid loss of cardiomyocyte function and leads to cell
death, possibly involving both necrotic and apoptotic pathways.
Effects of bh/c on cardiomyocyte calcium transients
Because the GBS bh/c toxin has previously been shown to form
pores in target cell membranes with the potential for disrupting
cytosolic ion concentrations, cytosolic calcium levels during
exposure to hemolysin were assessed using the ratiometric dye,
fura-2. Fura-2AM-loaded neonatal rat primary cardiomyocytes
were treated with either GBS WT or Dbh/c mutant extracts, and
calcium transients observed at 2 min intervals over time. Normal-
appearing calcium transients were observed in the first several min
following exposure to either WT or Dbh/c mutant extracts.
Figure 1. GBS bh/c effects on HL-1 cardiomyocyte contractility.
(A) Contractility rate (beats per min) was determined for HL-1 cells
before and 1 hr after exposure to live WT or Dbh/c mutant GBS bacteria
(multiplicity of infection=1.0) or hemolysin extracts (1:100). Graphs
depict percentage of the initial contractility rate following treatment. (B)
Number of contractile cells per high power field (hpf) prior to and
60 min after exposure to extracts from WT or Dbh/c mutant GBS. Data
represent the mean +/2 SD from three separate experiments.
doi:10.1371/journal.pone.0002446.g001
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per minute) markedly increased for cells exposed to WT but not
Dbh/c mutant GBS extract (Fig. 3A and B). Furthermore, by
10 min, the length of calcium transients markedly decreased in
primary cardiomyocytes exposed to the WT extract, with a slight
and statistically significant decrease observed starting at 4 min
(Fig. 3C). Baseline cytosolic calcium levels also appeared slightly
elevated starting at 12 min of exposure to GBS WT Extract and
remained so out to at least 20 min (data not shown), perhaps
suggesting an unregulated entry of extracellular calcium into cells,
becoming apparent when calcium transients were no longer
detectable. Both the rate and length of transients remained
unchanged at all timepoints studied up to 20 min for primary
cardiomyocytes exposed to extracts from the GBS Dbh/c mutant
(Fig. 3A–C) or with buffer alone (data not shown). The detrimental
effect of GBS bh/c on calcium transients was fully inhibited by co-
treatment with 2 mg/ml DPPC (Fig. 3A–C).
GBS bh/c disrupts mitochondrial membrane potential in
cardiomyocytes
Because of its importance in cell viability and function, the effect
of bh/c on mitochondrial membrane potential was investigated.
HL-1 cells were loaded with the mitochondrial membrane potential
indicator, TMRE, and loaded cells were treated with extracts of
WT or Dbh/c mutant GBS for 1 h. Membrane potential was
assessed by FACS analysis of TMRE staining of trypsinized cells. As
shown in Fig. 4, cells exposed to extracts of WT GBS exhibited a
high percentage of cells with reduced TMRE staining, indicative of
a loss of mitochondrial membrane potential, approaching the loss of
potential observed after treatment with the positive control agent,
FCCP. Conversely, the percentage of GBS Dbh/c extract-exposed
cardiomyocytes with reduced TMRE staining did not differ
significantly from media control (Fig. 4). Finally, the effect of WT
GBS bh/c extract on TMRE staining was significantly reduced
when cells were co-treated with DPPC (Fig. 4).
Discussion
The precise etiology of mortality in early-onset GBS sepsis is not
known, but development of hypotension is a discriminating feature
and an important predictor of fatal outcome [8,9]. Experiments in
a rabbit model following intravenous infusion of GBS revealed a
dramatic decrease in the first derivative of left ventricular pressure
over time (LVdP/dt), decreased cardiac output, and decreased
mean arterial pressure, yet no changes in systemic vascular
resistance or left ventricular end diastolic pressure, a pattern that
points to a primary role for myocardial dysfunction in GBS sepsis
[11]. Our present study examined for the first time the direct
interaction between this pathogen and cardiomyocytes, using an in
vitro tissue culture system. We find that GBS induces cardiomy-
ocyte dysfunction and promotes cardiomyocyte death in a fashion
that depends upon expression of its b-h/c toxin.
Figure 2. GBS bh/c effects on HL-1 cardiomyocyte viability. (A) Trypan blue staining of HL-1 cells exposed for 1 h to extracts (1:200 dilution)
from WT GBS in the absence or presence of DPPC (2 mg/ml) or to similar extracts of Dbh/c mutant GBS. (B) Analysis of TUNEL staining by flow
cytometry. Percent TUNEL positive HL-1 cells that had been treated for 1 h with extracts (1:200) of WT GBS in the absence or presence of 2 mg/ml
DPPC or with extracts from Dbh/c mutant GBS. Apoptosis data represent the mean +/2 SD from three separate experiments.
doi:10.1371/journal.pone.0002446.g002
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models of invasive infection have not examined cardiac function
directly, although the presence of the toxin was significantly
correlated to development of hypotension [28,33] and overall
mortality [25,27,29]. Here we show a direct effect of GBS bh/c on
cardiomyocyte viability and contractility as well as in maintenance
of normal calcium transients. We observed that in cardiomyocytes
exposed to GBS bh/c, the rate of calcium transients per minute
was greatly increased, and the average length of transients was
significantly decreased, immediately prior to complete elimination
of transient formation. Previous studies have shown that early
apoptotic changes in adult cardiomyocytes include unusual
contractile activity and increases in calcium transients that are
believed to be involved in the initiation of the cell death pathway
[34]. The rapid pore-forming activity of GBS bh/c appears to
accelerate the kinetics of processes such as increases in calcium
transient frequency in comparison to other pathologic conditions
such as chronic cardiac failure. It is possible that parallel
pathophysiologic changes are induced by other bacterial pore-
forming toxins such as S. aureus a-toxin and E. coli hemolysin,
which have been shown to affect contractility of isolated perfused
hearts [17,18], but have yet to be studied in isolated cardiomy-
ocytes for potential effects on calcium transients or apoptosis.
Our data show a rapid loss of cardiomyocyte contractility and
viability induced by GBS through the action of its bh/c toxin,
which may involve both necrotic and apoptotic mechanisms. We
observed effects on cardiomyocyte functionality within minutes of
exposure to the toxin. A detectable rise in intracellular calcium
within 20 min of bh/c exposure may precipitate downstream
effects such as loss of mitochondrial membrane polarization, as
apparent in our TMRE studies after 1 h. Recently, inhibition of
mitochondrial membrane permeability transition using immuno-
suppressive agents or mitochondrial Bcl-2 overexpression has been
shown to inhibit sepsis-induced myocardial dysfunction and
mortality in a mouse model [35]. Our finding that bh/c-induced
apoptosis was not inhibited by intracellular and extracellular
Figure 3. Calcium transients of primary rat neonatal ventricular cardiomyocytes upon exposure to GBS bh/c (1:200 dilution). (A)
Representative 30 sec calcium transient profiles of primary neonatal ventricular cardiomyocytes exposed to extracts of WT or Dbh/c mutant GBS or to
WT extracts in the presence of 2 mg/ml DPPC for up to 12 min. (B) The number of calcium transients per minute was calculated prior to and during
exposure to extracts of either WT or bh/c mutant GBS. Data represent the percent of initial (at time 0) number of calcium transients per minute +/2
SD from three independent experiments; *P,0.04, **P,0.03. (C) Length of calcium transients was calculated from five randomly selected transients
for each 30 sec recording. Data represent the percent of initial (at time 0) average length of calcium transient mean +/2 SD from three independent
experiments; *P, 0.05.
doi:10.1371/journal.pone.0002446.g003
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calcium-independent.
We hypothesize that bh/c secreted and accumulated during
systemic neonatal infection with GBS could affect maintenance of
normal calcium transients in intact cardiomyocytes and potentially
lead to cell death in localized areas of cardiac tissue, thereby
promoting asynchronous contractile activity and myocardial
dysfunction and even death. In our previous work examining
GBS pulmonary infection in neonatal rabbits, developmentsys-
temic infection was correlated to b-h/c activity [26], and we report
here an example of a GBS microabscesses within the cardiac tissue
of a rabbit pup infected with the WT strain from that study (Figure
S1). GBS is also an uncommon yet well-documented cause of
infective endocarditis in adult populations. GBS endocarditis is an
aggressive disease with a high rate of local and systemic
complications, with ,40% of patients requiring surgery because
of extensive valve destruction and fatal outcome in more than 1/3
of patients [36,37]. It is possible therefore that GBS bh/c induced
cardiomyocyte cell death also contributes to the poor prognosis of
this syndrome.
Our earlier published work has demonstrated a definitive role
for bh/c in cytotoxicity to lung epithelial cells [23], pulmonary
endothelial cells [38], brain endothelial cells [24], and macro-
phages [25]. Together with the findings of the present study
regarding cardiomyocytes, this broad-spectrum cytolysin likely
contributes in multiple fashions to the life-threatening manifesta-
tions of severe early onset GBS disease. Pharmacological agents,
including phosopholipid DPPC, that are designed to block bh/c
cytotoxicity could represent a therapeutic strategy to mitigate
cardiac and other organ dysfunction during such infections. Of
note, DPPC is already used as a major component of surfactant
administered intratracheally in replacement therapy for respirato-
ry distress syndrome of the neonate and certain liposomal
preparations for delivery of systemic agents (e.g. amphotericin).
Methods
Cells and Reagents
HL-1 atrial cardiomyocytes [39] were a kind gift of Dr. William
Claycomb (Louisiana State University Medical Center). Neonatal rat
ventricular cardiomyocytes were isolated from rat pups and as
previously described [40]. Our investigations conform with the Guide
for the Care and Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 85-23, revised 1996).
Todd-Hewitt broth (THB) and agar (THA) were obtained from
Hardy Diagnostics (Santa Maria, CA). GBS strains used were NCTC
10/84 (hereafter designated WT), a hemolytic serotype V clinical
isolate fromneonatal sepsis [23], and its corresponding isogenic b/hc-
d e f i c i e n ta l l e l i cr e p l a c e m e n tm u t a n tN C T C : cylEDcat [21], hereafter
designated Dbh/c. Fura-2AM, APO-Brdu TUNEL Assay Kit,
BAPTA-AM, FCCP (carbonylcyanide p-(trifluoromethoxy)phenyl-
hydrazone), and TMRE (tetramethylrhodamine ethyl ester) were
each obtained from Invitrogen/Molecular Probes (Eugene, OR).
Fibronectin used to coat tissue culture dishes and plates and the bh/c
inhibitor DPPC (1,2 dipalmitoyl-sn-glycero-3-phosphocholine) were
obtained from Sigma-Aldrich (St. Louis, MO).
GBS bh/c and DPPC preparation
Partially purified hemolysin extracts were prepared using a
modification of a previously published protocol [32]. Briefly,
overnight cultures of WT and Dbh/c GBS grown in parallel in
THB were diluted 1:20 in 500 ml fresh THB and grown to
A600=0.4. The bacteria were then pelleted and washed twice in
Dulbecco’s phosphate-buffered saline (DPBS - Gibco). Washed
bacteria were next resuspended in DPBS containing 1% glucose
and 1% soluble starch (Difco) and incubated for 1 h at 37uC.
Bacteria were then pelleted, and supernatant containing starch-
stabilized bh/c was 0.2 mm-filtered and then precipitated in an
equal volume of ice-cold methanol. The methanol precipitate was
dried, resuspended in 1 ml of PBS, filter-sterilized, and stored at
4uC. Each WT and Dbh/c mutant GBS extract used in these
experiments was assayed for hemolytic titer on sheep erythrocytes
prior to use in cardiomyocyte experiments; extracts from WT GBS
demonstrated hemolytic activity following dilution to 1:2500,
while Dbh/c mutant extracts exhibited no hemolytic activity at a
1:20 dilution. DPPC was prepared fresh for each experiment by
sonicating 20 mg/ml DPPC in media on a narrow tip sonicator
(550 Sonic Dismembrator, Fisher Scientific, Pittsburgh, PA) for
two 45 second pulses (setting 3).
Cardiomyocyte viability and contractility assays
HL-1 cardiomyocytes were grown in 5% CO2 at 37uCi n
supplemented Claycomb media as previously described [41]. For
assays of viability and contractility, ,10
5 cells/well were plated in
fibronectin-coated 12 well plates (Becton-Dickinson, Franklin
Lakes, NJ) and allowed to grow for 2–3 days until contractile
activity was observed. On the day of the assay, media was replaced
with fresh media, and cells were allowed to equilibrate for an
additional 1 h at 37uC. For assays using intact bacteria, WT and
Dbh/c mutant GBS were grown to A600=0.4, washed twice in
DPBS, and resuspended to A600=0.4 in Claycomb media.
Washed bacteria were added at a multiplicity of infection
(MOI)=1.0 and incubated with the cells for 1 h prior to
assessment of cardiomyocyte viability or contractility. WT and
Dbh/c cell-free extracts were added to the HL-1 cells at known
dilutions ranging from 1:100 to 1:10,000 and incubated as for the
intact bacteria. Assessment of cell viability and contractility was
performed using a Zeiss Axiovert 40 CFL inverted microscope.
For viability studies, cells were gently rinsed three times in DPBS
and fixed in 1% formalin for 30 min prior to trypan blue and eosin
staining. Contractility rate was enumerated from a 30 sec count of
the synchronously contractile cells in three random fields. Number
of contractile cells per high power field (hpf) at 4006magnification
was assessed for three randomly-chosen fields.
Figure 4. TMRE staining of HL-1 cells exposed to bh/c extracts.
HL-1 cardiomyocytes were loaded with TMRE (50 nM) for 30 min prior
to exposure to WT or Dbh/c mutant hemolysin extracts (1:200 dilution)
or FCCP (5 uM) for 1 h. Cells were rinsed in DPBS, trypsinized, and
analyzed for TMRE staining by flow cytometry. Data represent mean
percent of cells with reduced TMRE staining +/2 SD from three
separate experiments.
doi:10.1371/journal.pone.0002446.g004
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HL-1 cardiomyocytes were added to 6-well plates (BD Falcon,
Franklin Lakes, NJ) at ,5610
5 cells per well and incubated for 2 d
prior to assay. For the assay, media was replaced with fresh media,
and hemolysin extracts prepared from WT or Dbh/c mutant
bacteria added at 1:200 dilution. Where indicated, freshly-
prepared DPPC was added at a final concentration of 2 mg/ml
at the same time as the hemolysin. After 1 h, the cells were gently
rinsed in DPBS, trypsinized, and fixed in 1% formalin for 30 min.
Cells were end-labeled per Apo-Brdu TUNEL Assay kit
instructions and then analyzed for staining by flow cytometry
(BD FACSCalibur).
Measurement of calcium transients
Freshly-isolated rat cardiomyocytes were plated at 0.9610
6 cells
on fibronectin-coated 35 mm glass bottomed dishes and allowed
to grow for 2 d prior to use. Media was replaced daily until assay,
and cells were assessed for contractile activity prior to fura-2AM
treatment. Cells were loaded with 5 mM fura-2AM at room
temperature for 30 min in clear DMEM followed by two rinses in
clear DMEM and a 30 min incubation to allow full cleavage of
fura-2AM to fura-2. Cells were then analyzed on an inverted
microscope, and fluorescence recorded with a dual excitation
fluorescence photomultiplier system (IonOptix) as previously
described [42]. Baseline recording was performed prior to addition
of hemolysin extracts (1:200 dilution), and calcium transients were
recorded for 30 sec time intervals every 2 min for up to 20 min.
Where indicated, DPPC was added at 2 mg/ml final concentra-
tion at the time of hemolysin addition. Both the number of calcium
transients per 30 sec and the length of the transients at baseline
(from an average of five randomly-chosen transients per 30 second
recording) were calculated for each group. Data reported
represent the average of three separate experiments.
Mitochondrial membrane depolarization studies
HL-1 cardiomyocytes were plated as for the apoptosis studies in
section 2.4. Cells were loaded with 50 nM TMRE for 30 min at
37uC and rinsed gently prior to addition of hemolysin preparations
(1:200) for one hour. Cells were then rinsed in DPBS, trypsinized,
and analyzed for TMRE staining by flow cytometry (BD
FACSCalibur) at 582 nm. As a positive control for mitochondrial
membrane depolarization, cells were exposed to the H
+ iono-
phore, FCCP (5 mM), for 30 minutes prior to analysis.
Statistical analysis
Data are expressed as mean +/2 SD. Between group
differences were analyzed by Mann-Whitney U-test. Differences
were considered statistically significant at P,0.05.
Supporting Information
Figure S1 Micrograph of group B Streptococcus microabscess in
cardiac tissue of neonatal rabbit infected by direct intratracheal
inoculation with resultant bacteremia (challenge model described
in Hensler et al. J Infect Dis 2005; 191:1287-91). Cell death and
necrosis of surrounding cardiomyocytes is apparent.
Found at: doi:10.1371/journal.pone.0002446.s001 (7.34 MB TIF)
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